VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | Phase II trial show nilotinib achieves remission Philadelphia-positive acute lymphocytic leukaemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt, Germany) discusses a Trial of the European Working Group for Adult ALL (EWALL-PH-02), which evaluated nilotinib and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1-positive acute lymphoblastic leukaemia.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter